<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170417033485N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-20</date_registration>
      <primary_sponsor>Bagheiat-allah University of Medical Sciences</primary_sponsor>
      <public_title>The Effectiveness of Dialectical Behavior Therapy and repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex on Symptoms of Borderline Personality Disorder: A Single blind randomized controlled clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>The Effectiveness of Dialectical Behavior Therapy and repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex on Symptoms of Borderline Personality Disorder: A Single blind randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56577</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: For randomization, the restricted randomization method of the type of permuted block randomization (Random quadruple blocks) will be used and for this purpose, the online system sealedenvelop.com will be used, which randomly divides the four main intervention groups (D, C, B, E, …). Then the first patient enters group D, the second patient in group C, etc. until the groups are completed, Blinding description: Once the relevant groups have been identified, the study is designed in such a way that, except for the lead researcher, none of the subjects and all those who come into contact with them unaware of the assignment of the study groups. For this purpose, first of all, all patients have the idea that each of them receives the intervention and are also unaware of the type of intervention. Second, other colleagues who are in contact with patients along the study path do not know the study group and its type.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Borderline Personality Disorder.</hc_freetext>
      <i_freetext>Intervention 1: Dialectical Behavior Therapy: Dialectical behavioral therapy is a special type of cognitive behavioral therapy which developed in the late of 1980s by Marsha Linhan to help better treatment of borderline personality disorder; But it is currently used to treat a variety of psychological disorders. In this study, two groups will receive dialectical behavior therapy (DBT). The first is the group that receives DBT alone, and the group that receives it after receiving repetitive Transcranial Magnetic Stimulation (rTMS) sessions. DBT will be performed as group psychotherapy for 8 to 12 sessions (Linhan, 1993). After the intervention, questionnaires and Flanker test will be taken immediately after and one month later. Intervention 2: repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. In this study, a group will receive real rTMS and a placebo group received it artificially. In the rTMS group, rTMS will be performed with the device of Magstim Company under the supervision of a psychiatrist and a physiologist of the psychiatry center located in Imam Hossein (AS) Hospital. As mentioned, according to previous studies, the target area for this purpose will be right dorsolateral prefrontal cortex (right DLPFC) with a frequency of 10 Hz for 8 to 10 sessions of 20 minutes per day for two weeks. The placebo group will lie on the device but will not recieve any stimuluatin. After the intervention, questionnaires and Flanker test will be taken immediately after and one month later. Intervention 3: Dialectical Behavior Therapy + repetitive Transcranial Magnetic Stimulation: This group receives two interventions and after performing and completing rTMS sessions (10 Hz for 8 to 10 sessions for 20 minutes per day for two weeks on DLPFC right hemisphere), 8 to 12 DBT sessions (Linhan, 1993) will be done. After the intervention, questionnaires and Flanker test will be taken immediately after and one month later. Intervention 4: Negative control group (waiting list) with sham brain stimulation: This group includes borderline patients who do not receive any intervention and whose brain stimulation is artificial. Sham rTMS stimulation was delivered using the same stimulation parameters and at the same site; however, a sham coil was used. Intervention 5: Positive control group includes healthy people: Healthy people who do not receive any intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All personal data of the study participants can be shared after encoding individuals.

When:
Data release time will be available after the relevant articles are published.

To whom:
All researchers

Conditions:
If the articles of this project are cited to.

Where to obtain:
Alireza Mohammadi

How to obtain:
By sending an email to the project manager

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alirza Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vanak Square, Mulla Sadra Street, Sheikh Baha'i Intersection</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435916471</zip>
        <telephone>+98 21 8862 3188</telephone>
        <email>ar.mohammadi@bmsu.ac.ir</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>C5 uinit, No 5, Kharami Street, Mulla Sadra Street, Vanak Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435916471</zip>
        <telephone>+98 21 8862 3188</telephone>
        <email>ar.mohammadi@bmsu.ac.ir</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of an experienced psychiatrist and possession of diagnostic properties of borderline personality disorder based on DSM-5 and SCID-5-PD
Minimum diploma education
Age range between 18 and 45 years
Failure to receive psychological treatment in the past with the aim of treating borderline personality disorder
At least five times self injury (self-harm) in the past</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Having prominent psychotic symptoms and uncontrollable suicidal thoughts
Having delusional disorders
Patients undergoing psychotherapy at the time of selection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F60.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Borderline personality disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Dialectical Behavior Therapy: Dialectical behavioral therapy is a special type of cognitive behavioral therapy which developed in the late of 1980s by Marsha Linhan to help better treatment of borderline personality disorder; But it is currently used to treat a variety of psychological disorders. In this study, two groups will receive dialectical behavior therapy (DBT). The first is the group that receives DBT alone, and the group that receives it after receiving repetitive Transcranial Magnetic Stimulation (rTMS) sessions. DBT will be performed as group psychotherapy for 8 to 12 sessions (Linhan, 1993). After the intervention, questionnaires and Flanker test will be taken immediately after and one month later.</i_keyword>
      <i_keyword>repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. In this study, a group will receive real rTMS and a placebo group received it artificially. In the rTMS group, rTMS will be performed with the device of Magstim Company under the supervision of a psychiatrist and a physiologist of the psychiatry center located in Imam Hossein (AS) Hospital. As mentioned, according to previous studies, the target area for this purpose will be right dorsolateral prefrontal cortex (right DLPFC) with a frequency of 10 Hz for 8 to 10 sessions of 20 minutes per day for two weeks. The placebo group will lie on the device but will not recieve any stimuluatin. After the intervention, questionnaires and Flanker test will be taken immediately after and one month later.</i_keyword>
      <i_keyword>Dialectical Behavior Therapy + repetitive Transcranial Magnetic Stimulation: This group receives two interventions and after performing and completing rTMS sessions (10 Hz for 8 to 10 sessions for 20 minutes per day for two weeks on DLPFC right hemisphere), 8 to 12 DBT sessions (Linhan, 1993) will be done. After the intervention, questionnaires and Flanker test will be taken immediately after and one month later.</i_keyword>
      <i_keyword>Negative control group (waiting list) with sham brain stimulation: This group includes borderline patients who do not receive any intervention and whose brain stimulation is artificial. Sham rTMS stimulation was delivered using the same stimulation parameters and at the same site; however, a sham coil was used.</i_keyword>
      <i_keyword>Positive control group includes healthy people: Healthy people who do not receive any intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The score of Borderline Personality Disorder Severity Index (BPDSI). Timepoint: Before the intervention (Pre-test), after the intervention (Post-test) and one month after the intervention (Following). Method of measurement: Borderline Personality Disorder Severity Index (BPDSI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Distress Tolerance Scale (DTS). Timepoint: Before the intervention (Pre-test), after the intervention (Post-test) and one month after the intervention (Following). Method of measurement: Distress Tolerance Scale (DTS) Questionnaire.</sec_outcome>
      <sec_outcome>Barratt Impulsiveness Scale. Timepoint: Before the intervention (Pre-test), after the intervention (Post-test) and one month after the intervention (Following). Method of measurement: Barratt Impulsiveness Scale Questionnaire.</sec_outcome>
      <sec_outcome>Difficulties in Emotion Regulation Scale. Timepoint: Before the intervention (Pre-test), after the intervention (Post-test) and one month after the intervention (Following). Method of measurement: Difficulties in Emotion Regulation Scale Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>does not have</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-25</approval_date>
        <contact_name>Biomedical Research Ethics Committee of Baqiyatallah Hospital</contact_name>
        <contact_address>Vanak Square, Mulla Sadra Street, Sheikh Baha'i Intersection Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
